Literature DB >> 28029155

Glomerular disease: Rituximab therapy for IgA nephropathy.

Jürgen Floege1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28029155     DOI： 10.1038/nrneph.2016.188

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  11 in total

1.  Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Authors:  Hitoshi Suzuki; Run Fan; Zhixin Zhang; Rhubell Brown; Stacy Hall; Bruce A Julian; W Winn Chatham; Yusuke Suzuki; Robert J Wyatt; Zina Moldoveanu; Jeannette Y Lee; James Robinson; Milan Tomana; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

Review 2.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

Review 3.  Pathology of IgA nephropathy.

Authors:  Ian S D Roberts
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

4.  A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Authors:  Richard A Lafayette; Pietro A Canetta; Brad H Rovin; Gerald B Appel; Jan Novak; Karl A Nath; Sanjeev Sethi; James A Tumlin; Kshama Mehta; Marie Hogan; Stephen Erickson; Bruce A Julian; Nelson Leung; Felicity T Enders; Rhubell Brown; Barbora Knoppova; Stacy Hall; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 10.121

Review 5.  The mucosa-kidney axis in IgA nephropathy.

Authors:  Jürgen Floege; John Feehally
Journal:  Nat Rev Nephrol       Date:  2015-12-30       Impact factor: 28.314

Review 6.  Rituximab in primary membranous nephropathy: first-line therapy, why not?

Authors:  Paolo Cravedi; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Nephron Clin Pract       Date:  2014-11-22

7.  Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.

Authors:  Ronald J Hogg; R Curtis Bay; J Charles Jennette; Richard Sibley; Sumit Kumar; Fernando C Fervenza; Gerald Appel; Daniel Cattran; Danny Fischer; R Morrison Hurley; Jorge Cerda; Brad Carter; Beverly Jung; German Hernandez; Debbie Gipson; Robert J Wyatt
Journal:  Am J Kidney Dis       Date:  2015-07-21       Impact factor: 8.860

8.  Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

Authors:  Carlo Manno; Diletta Domenica Torres; Michele Rossini; Francesco Pesce; Francesco Paolo Schena
Journal:  Nephrol Dial Transplant       Date:  2009-07-23       Impact factor: 5.992

9.  Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.

Authors:  Jicheng Lv; Hong Zhang; Yuqing Chen; Guangtao Li; Lei Jiang; Ajay K Singh; Haiyan Wang
Journal:  Am J Kidney Dis       Date:  2008-10-19       Impact factor: 8.860

10.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Authors:  Thomas Rauen; Frank Eitner; Christina Fitzner; Claudia Sommerer; Martin Zeier; Britta Otte; Ulf Panzer; Harm Peters; Urs Benck; Peter R Mertens; Uwe Kuhlmann; Oliver Witzke; Oliver Gross; Volker Vielhauer; Johannes F E Mann; Ralf-Dieter Hilgers; Jürgen Floege
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.